An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor

Zhang, Xuewu, Gureasko, Jodi, Shen, Kui, Cole, Philip A., Kuriyan, John·2006·Cell
DOI 10.1016/j.cell.2006.05.013

Cited by (1,001)

Items 401–500 of 1,001

  1. Novel drugs targeting EGFR and HER2 exon 20 mutations in metastatic NSCLC
    Iosune Baraibar, Laura Mezquita, Ignacio Gil Bazo, David Planchard · 2020 · Critical Reviews in Oncology/Hematology
  2. Circulating DNA in diagnosis and monitoring EGFR gene mutations in advanced non-small cell lung cancer.
    Paola Bordi, Marzia Del Re, Romano Danesi, Marcello Tiseo · 2015 · PubMed Central
  3. Rule-Based Modelling and Model Perturbation
    Vincent Danos, Jérôme Ferêt, Walter Fontana, Russ Harmer, Jean Krivine · 2009 · Lecture notes in computer science
  4. Transmembrane helix orientation influences membrane binding of the intracellular juxtamembrane domain in Neu receptor peptides
    Chihiro Matsushita, Hiroko Tamagaki, Yudai Miyazawa, Saburo Aimoto, Steven O. Smith, Takeshi Sato · 2013 · Proceedings of the National Academy of Sciences
  5. Impaired SHP2-Mediated Extracellular Signal-Regulated Kinase Activation Contributes to Gefitinib Sensitivity of Lung Cancer Cells with Epidermal Growth Factor Receptor–Activating Mutations
    Matthew J. Lazzara, Keara M. Lane, Richard Chan, Paul Jasper, Michael B. Yaffe, Peter Karl Sorger, Tyler Jacks, Benjamin G. Neel, Douglas A. Lauffenburger · 2010 · Cancer Research
  6. Insights into the evolution of the ErbB receptor family and their ligands from sequence analysis.
    Richard A. Stein, James V. Staros · 2006 · BMC Evolutionary Biology
  7. Structural Basis for Inhibition of Mutant EGFR with Lazertinib (YH25448)
    Heppner, David E., Wittlinger, Florian, Beyett, Tyler S., Shaurova, Tatiana, Urul, Daniel A., Buckley, Brian, Pham, Calvin D., Schaeffner, Ilse K., Yang, Bo, Ogboo, Blessing C. et al. · 2022 · ACS Medicinal Chemistry Letters
  8. Her4 and Her2/neu Tyrosine Kinase Domains Dimerize and Activate in a Reconstituted in Vitro System
    John D. Monsey, Wei Shen, Paul H. Schlesinger, Ron Bose · 2009 · Journal of Biological Chemistry
  9. Perspectives for the use of structural information and chemical genetics to develop inhibitors of Janus kinases
    Claude Haan, Iris Behrmann, Serge Haan · 2010 · Journal of Cellular and Molecular Medicine
  10. A critical role for HER3 in HER2-amplified and non-amplified breast cancers: function of a kinase-dead RTK.
    Nandini Dey, Casey B. Williams, Brain Leyland-Jones, Pradip K. De · 2015 · PubMed Central
  11. Altered conformational landscape and dimerization dependency underpins the activation of EGFR by α C– β 4 loop insertion mutations
    Zheng Ruan, Natarajan Kannan · 2018 · Proceedings of the National Academy of Sciences
  12. Defining the landscape of ATP-competitive inhibitor resistance residues in protein kinases
    Nicole S. Persky, Desiree Hernandez, M. Do Carmo, Lisa Brenan, Ofir Cohen, Shunsuke Kitajima, Utthara Nayar, A. Walker, Sasha Pantel, Y. Lee et al. · 2020 · Nature Structural & Molecular Biology
  13. Somatic Mutations of ErbB4
    Denis Tvorogov, Maria Sundvall, Kari J. Kurppa, Maija Hollmén, Susanna Repo, Mark S. Johnson, Klaus Elenius · 2008 · Journal of Biological Chemistry
  14. HER family in cancer progression: From discovery to 2020 and beyond
    Rakesh Kumar, Bijesh George, Marcia R. Campbell, Nandini Verma, Aswathy Mary Paul, Cecília Melo-Alvim, Leonor Ribeiro, M. Radhakrishna Pillai, Luís Costa, Mark M. Moasser · 2020 · Advances in cancer research
  15. Protein tyrosine kinase–substrate interactions
    Ron Bose, Marc A. Holbert, Kerry A. Pickin, Philip A. Cole · 2006 · Current Opinion in Structural Biology
  16. Allosteric Activation by Dimerization of the PknD Receptor Ser/Thr Protein Kinase from Mycobacterium tuberculosis
    Andrew E. Greenstein, Nathaniel Echols, T. Noelle Lombana, David King, Tom Alber · 2007 · Journal of Biological Chemistry
  17. Redox regulation of tyrosine kinase signalling: more than meets the eye
    Christopher M. Dustin, David E. Heppner, Miao-Chong Joy Lin, Albert van der Vliet · 2019 · The Journal of Biochemistry
  18. HER2 stabilizes EGFR and itself by altering autophosphorylation patterns in a manner that overcomes regulatory mechanisms and promotes proliferative and transformation signaling
    Zachary Hartman, Hua Zhao, Yehenew M. Agazie · 2012 · Oncogene
  19. Resistance to molecularly targeted therapy in non-small-cell lung cancer
    Tetsuhiko Asao, Fumiyuki Takahashi, Kazuhisa Takahashi · 2018 · Respiratory Investigation
  20. Growth Factor Identity Is Encoded by Discrete Coiled-Coil Rotamers in the EGFR Juxtamembrane Region
    Amy E. Doerner, Rebecca A. Scheck, Alanna Schepartz · 2015 · Chemistry & Biology
  21. Acetylation modulates prolactin receptor dimerization
    Li Ma, Jinsong Gao, Yingjie A. Guan, Xiaoyan Shi, Hao Zhang, Marina K. Ayrapetov, Zhe Zhang, Li Xu, Young‐Min Hyun, Minsoo Kim et al. · 2010 · Proceedings of the National Academy of Sciences
  22. The principle of conformational signaling
    Péter Tompa · 2016 · Chemical Society Reviews
  23. Bisphosphonates inactivate human EGFRs to exert antitumor actions
    Tony Yuen, Agnes Stachnik, Jameel Z. Iqbal, Miriam Sgobba, Yogesh K. Gupta, Ping Lü, Graziana Colaianni, Yaoting Ji, Ling-Ling Zhu, Se‐Min Kim et al. · 2014 · Proceedings of the National Academy of Sciences
  24. Copine-III interacts with ErbB2 and promotes tumor cell migration
    Constanze Heinrich, C Keller, Anne Boulay, Manuela Vecchi, M Bianchi, Ragna Sack, Susanne Lienhard, Stephan Duss, Jan Hofsteenge, Nancy E. Hynes · 2009 · Oncogene
  25. Allosteric Activation Mechanism of the Mycobacterium tuberculosis Receptor Ser/Thr Protein Kinase, PknB
    T. Noelle Lombana, Nathaniel Echols, Matthew C. Good, Nathan D. Thomsen, Ho Leung Ng, Andrew E. Greenstein, Arnold M. Falick, David King, Tom Alber · 2010 · Structure
  26. All Mammalian Hedgehog Proteins Interact with Cell Adhesion Molecule, Down-regulated by Oncogenes (CDO) and Brother of CDO (BOC) in a Conserved Manner
    Jennifer M. Kavran, Matthew D. Ward, Oyindamola Oladosu, Sabin Mulepati, Daniel J. Leahy · 2010 · Journal of Biological Chemistry
  27. Physical–chemical principles underlying RTK activation, and their implications for human disease
    Lijuan He, Kalina A. Hristova · 2011 · Biochimica et Biophysica Acta (BBA) - Biomembranes
  28. Different Epidermal Growth Factor Receptor (EGFR) Agonists Produce Unique Signatures for the Recruitment of Downstream Signaling Proteins
    Tom Ronan, Jennifer L. Macdonald-Obermann, Lorel Huelsmann, Nicholas J. Bessman, Kristen M. Naegle, LINDA JOY PIKE · 2016 · Journal of Biological Chemistry
  29. Understanding and exploiting substrate recognition by protein kinases
    Benjamin E. Turk · 2008 · Current Opinion in Chemical Biology
  30. Small Molecule Kinase Inhibitors as Anti-Cancer Therapeutics
    Osama Chahrour, Donald Cairns, Ziad Omran · 2012 · Mini-Reviews in Medicinal Chemistry
  31. Chronicles of EGFR Tyrosine Kinase Inhibitors: Targeting EGFR C797S Containing Triple Mutations
    Krishna Babu Duggirala, Yujin Lee, Kwangho Lee · 2021 · Biomolecules & Therapeutics
  32. Activation of Human VPS4A by ESCRT-III Proteins Reveals Ability of Substrates to Relieve Enzyme Autoinhibition
    Samuel A. Merrill, Phyllis I. Hanson · 2010 · Journal of Biological Chemistry
  33. Physiologic responses and gene diversity indicate olive alternative oxidase as a potential source for markers involved in efficient adventitious root induction
    Elisete Santos Macedo, Hélia Guerra Cardoso, Alejandro Hernández, Augusto Peixe, Alexios N. Polidoros, Alexandre Oliveira Ferreira, A.M. Cordeiro, Birgit Arnholdt‐Schmitt · 2009 · Physiologia Plantarum
  34. The ErbB4 CYT2 variant protects EGFR from ligand-induced degradation to enhance cancer cell motility
    Tai Kiuchi, Elena Ortiz Zapater, James Monypenny, Daniel R. Matthews, Lan K. Nguyen, Jody Barbeau, Oana Coban, Katherine Lawler, Brian Burford, Daniel J. Rolfe et al. · 2014 · Science Signaling
  35. Moderate and strong static magnetic fields directly affect EGFR kinase domain orientation to inhibit cancer cell proliferation
    Lei Zhang, Jihao Wang, Wenchao Wang, Wenchao Wang, Juanjuan Liu, Juanjuan Liu, Xingxing Yang, Xinmiao Ji, Yan Luo, Yubin Hou et al. · 2016 · Oncotarget
  36. The Association of Acquired T790M Mutation with Clinical Characteristics after Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma
    Yen-Hsiang Huang, Kuo-Hsuan Hsu, Jeng‐Sen Tseng, Kun‐Chieh Chen, Chia-Hung Hsu, Kang‐Yi Su, Jeremy J.W. Chen, Huei‐Wen Chen, Sung‐Liang Yu, Tsung‐Ying Yang et al. · 2018 · Cancer Research and Treatment
  37. IGF2 Autocrine-Mediated IGF1R Activation Is a Clinically Relevant Mechanism of Osimertinib Resistance in Lung Cancer
    Tadashi Manabe, Hiroyuki Yasuda, Hideki Terai, Harumi Kagiwada, Junko Hamamoto, Toshiki Ebisudani, Keigo Kobayashi, Keita Masuzawa, Shinnosuke Ikemura, Ichiro Kawada et al. · 2020 · Molecular Cancer Research
  38. ProtCID: a data resource for structural information on protein interactions
    Qifang Xu, Roland L. Dunbrack · 2020 · Nature Communications
  39. Two GxxxG-Like Motifs Facilitate Promiscuous Interactions of the Human ErbB Transmembrane Domains
    Claudia Escher, Florian Cymer, Dirk Schneider · 2009 · Journal of Molecular Biology
  40. Ectodomain orientation, conformational plasticity and oligomerization of ErbB1 receptors investigated by molecular dynamics
    Johannes Kästner, Hannes H. Loeffler, Selene K. Roberts, Marisa L. Martin-Fernandez, Martyn Winn · 2009 · Journal of Structural Biology
  41. Molecular basis for receptor tyrosine kinase A-loop tyrosine transphosphorylation
    Lingfeng Chen, William M. Marsiglia, Huaibin Chen, Joseph Katigbak, Hediye Erdjument‐Bromage, David J. Kemble, Lili Fu, Jinghong Ma, Gongqin Sun, Yingkai Zhang et al. · 2020 · Nature Chemical Biology
  42. Design, synthesis and biological evaluation of pyrazolyl-thiazolinone derivatives as potential EGFR and HER-2 kinase inhibitors
    Ke-Ming Qiu, Haihong Wang, Liming Wang, Yin Luo, Xianhui Yang, Xiaoming Wang, Hai‐Liang Zhu · 2012 · Bioorganic & Medicinal Chemistry
  43. Dynamic equilibrium between multiple active and inactive conformations explains regulation and oncogenic mutations in ErbB receptors
    Meytal Landau, Nir Ben‐Tal · 2007 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
  44. In Vitro Enzymatic Characterization of Near Full Length EGFR in Activated and Inhibited States
    Chen Qiu, Mary Katherine Tarrant, Tatiana N. Boronina, Patti A. Longo, Jennifer M. Kavran, Robert Norman Cole, Philip A. Cole, Daniel J. Leahy · 2009 · Biochemistry
  45. Structural insights into the inhibited states of the Mer receptor tyrosine kinase
    Xudong Huang, P.J. Finerty, John R. Walker, Christine Butler-Cole, Masoud Vedadi, Matthieu Schapira, Sirlester A. Parker, Benjamin E. Turk, Debra A. Thompson, Sirano Dhe‐Paganon · 2008 · Journal of Structural Biology
  46. Insights for the development of specific kinase inhibitors by targeted structural genomics
    O. Fedorov, M. Sundström, Brian D. Marsden, Stefan Knapp · 2007 · Drug Discovery Today
  47. Kinase-mediated quasi-dimers of EGFR
    Erez M. Bublil, Gur Pines, Gargi Surendra Patel, Gilbert O. Fruhwirth, Tony Ng, Yosef Yarden · 2010 · The FASEB Journal
  48. Cofactor-mediated conformational control in the bifunctional kinase/RNase Ire1
    A. Korennykh, P. Egea, A. Korostelev, J. Finer-Moore, R. Stroud, Chao Zhang, K. Shokat, P. Walter · 2011 · BMC Biology
  49. The Extracellular Domain of Fibroblast Growth Factor Receptor 3 Inhibits Ligand-Independent Dimerization
    Lirong Chen, Jesse K. Placone, Lawrence Novicky, Kalina A. Hristova · 2010 · Science Signaling
  50. Early clinical development of epidermal growth factor receptor targeted therapy in breast cancer
    Naoko Matsuda, Bora Lim, Xiaoping Wang, Naoto Tada Ueno · 2017 · Expert Opinion on Investigational Drugs
  51. Structure and function of RET in multiple endocrine neoplasia type 2
    Iván Plaza-Menacho · 2017 · Endocrine Related Cancer
  52. Complex Crystal Structures of EGFR with Third-Generation Kinase Inhibitors and Simultaneously Bound Allosteric Ligands
    Janina Niggenaber, Leonie Heyden, Tobias Grabe, Matthias Philipp Müller, Jonas Lategahn, Daniel Rauh · 2020 · ACS Medicinal Chemistry Letters
  53. Signalling dynamics in embryonic development
    Katharina F. Sonnen, Claudia Y. Janda · 2021 · Biochemical Journal
  54. TMEM25 inhibits monomeric EGFR-mediated STAT3 activation in basal state to suppress triple-negative breast cancer progression
    Jing Bi, Zhihui Wu, Xin Zhang, Taoling Zeng, Wanjun Dai, Ningyuan Qiu, Mingfeng Xu, Yikai Qiao, Lang Ke, Jiayi Zhao et al. · 2023 · Nature Communications
  55. Drug-resistant EGFR mutations promote lung cancer by stabilizing interfaces in ligand-free kinase-active EGFR oligomers
    R. Sumanth Iyer, Sarah R. Needham, Ioannis Galdadas, Benjamin Michael Davis, Selene K. Roberts, Rico C.H. Man, Laura C. Zanetti-Domingues, David T. Clarke, Gilbert O. Fruhwirth, Peter J. Parker et al. · 2024 · Nature Communications
  56. Current role of EGF receptor monoclonal antibodies and tyrosine kinase inhibitors in the management of head and neck squamous cell carcinoma
    Ana Karković Marković, Christine H. Chung · 2012 · Expert Review of Anticancer Therapy
  57. The Energy Landscape Analysis of Cancer Mutations in Protein Kinases
    Anshuman Dixit, Gennady M. Verkhivker · 2011 · PLoS ONE
  58. Choline Kinase Alpha as an Androgen Receptor Chaperone and Prostate Cancer Therapeutic Target
    Mohammad Asim, Charles E. Massie, Folake A. Orafidiya, Nelma Pértega‐Gomes, Anne Yvonne Warren, Mohsen Esmaeili, Luke A. Selth, Heather Ireland Zecchini, Katarina Luko, Arham Qureshi et al. · 2015 · JNCI Journal of the National Cancer Institute
  59. WHSC1L1-mediated EGFR mono-methylation enhances the cytoplasmic and nuclear oncogenic activity of EGFR in head and neck cancer
    Vassiliki Saloura, Theodore Vougiouklakis, Makda Getachew Zewde, Xiaolan Deng, Kazuma Kiyotani, Jae-Hyun Park, Yo Matsuo, Mark William Lingen, Takehiro Suzuki, Naoshi Dohmae et al. · 2017 · Scientific Reports
  60. Membrane-permeable Calmodulin Inhibitors (e.g. W-7/W-13) Bind to Membranes, Changing the Electrostatic Surface Potential
    Parijat Sengupta, Marı́a José Ruano, Francesc Tebar, Urszula P. Golebiewska, Ірина Зайцева, Carlos Enrich, Stuart McLaughlin, Antonio Villalobo · 2007 · Journal of Biological Chemistry
  61. Epidermal growth factor receptor in osteosarcoma: expression and mutational analysis
    Yong Hannah Wen, Hartmut Koeppen, Roberto Garcia, Luis A. Chiriboga, Branden Tarlow, Brock A. Peters, Charles W. Eigenbrot, Herman T. Yee, German C. Steiner, MARIA ALBA GRECO · 2007 · Human Pathology
  62. Allosteric Protein Kinase Regulation by Pseudokinases: Insights from STRAD
    Thanashan Rajakulendran, Frank Sicheri · 2010 · Science Signaling
  63. Epidermal growth factor receptor activation in prostate cancer by three novel missense mutations
    C Q Cai, Yi Peng, Michael T Buckley, Jian‐Jun Wei, Fanny Fanrong Chen, Leonard Liebes, William L. Gerald, Matthew R. Pincus, Iman Osman, P Lee · 2008 · Oncogene
  64. Spatio-temporal modeling of signaling protein recruitment to EGFR
    Ming-yu Hsieh, Shujie Yang, Mary Ann Raymond‐Stintz, Jeremy S. Edwards, Bridget Smith Wilson · 2010 · BMC Systems Biology
  65. Epidermal growth factor can be used in lieu of follicle-stimulating hormone for nuclear maturation of porcine oocytes in vitro
    Sang Jun Uhm, Mukesh Kumar Gupta, J.H. Yang, Hak‐Jae Chung, T.S. Min, H.T. Lee · 2010 · Theriogenology
  66. The role of cooperativity with Src in oncogenic transformation mediated by non-small cell lung cancer-associated EGF receptor mutants
    Byung Min Chung, Manjari Dimri, Manju George, Alagarsamy Lakku Reddi, G Chen, Vimla Band, Hamid Band · 2009 · Oncogene
  67. Structural basis for ALK2/BMPR2 receptor complex signaling through kinase domain oligomerization
    Christopher Agnew, Pelin Ayaz, Risa Kashima, Hanna S. Loving, Prajakta Ghatpande, Jennifer E. Kung, Eric S. Underbakke, Yibing Shan, David Elliot Shaw, Akiko Hata et al. · 2021 · Nature Communications
  68. GCN2 kinase activation by ATP-competitive kinase inhibitors
    Colin P. Tang, Owen Clark, John R. Ferrarone, Carl Campos, Alshad S. Lalani, John D. Chodera, Andrew M. Intlekofer, Olivier Elemento, Ingo K. Mellinghoff · 2021 · Nature Chemical Biology
  69. New developments in the treatment of ovarian cancer—future perspectives
    Juanita Suzanne Lopez, Susana N. Banerjee, Stuart B. Kaye · 2013 · Annals of Oncology
  70. Untangling Dual-Targeting Therapeutic Mechanism of Epidermal Growth Factor Receptor (EGFR) Based on Reversed Allosteric Communication
    Yuran Qiu, Xiaolan Yin, Xinyi Li, Yuanhao Wang, Qiang Fu, Renhua Huang, Shaoyong Lu · 2021 · Pharmaceutics
  71. αC Helix as a Switch in the Conformational Transition of Src/CDK-like Kinase Domains
    He Huang, Ruijun Zhao, Bradley M. Dickson, Robert D. Skeel, Carol Beth Post · 2012 · The Journal of Physical Chemistry B
  72. Synthesis, molecular modeling and biological evaluation of 2-(benzylthio)-5-aryloxadiazole derivatives as anti-tumor agents
    Kai Liu, Xiang Lu, Hongjia Zhang, Juan Sun, Hai‐Liang Zhu · 2011 · European Journal of Medicinal Chemistry
  73. Characterization of Membrane Protein Interactions in Plasma Membrane Derived Vesicles with Quantitative Imaging Förster Resonance Energy Transfer
    Sarvenaz Sarabipour, Nuala Del Piccolo, Kalina A. Hristova · 2015 · Accounts of Chemical Research
  74. A Structural Atlas of Kinases Inhibited by Clinically Approved Drugs
    Qi Wang, Julie Anne Zorn, John Kuriyan · 2014 · Methods in enzymology on CD-ROM/Methods in enzymology
  75. RETRACTED: The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility
    Jeroen J. Lammerts van Bueren, Wim K. Bleeker, Annika Brännström, Anne von Euler, Magnus Jansson, Matthias Peipp, Tanja Schneider‐Merck, Thomas Valerius, Jan G. J. van de Winkel, Paul W.H.I. Parren · 2008 · Proceedings of the National Academy of Sciences · Retracted
  76. Amphiregulin in cellular physiology, health, and disease: Potential use as a biomarker and therapeutic target
    Siddharth S. Singh, Shashi Bhushan Chauhan, Awnish Kumar, Shashi Bhushan Kumar, Christian R. Engwerda, Shyam Sundar, Rajiv Kumar · 2021 · Journal of Cellular Physiology
  77. Identification of Disulfide-linked Dimers of the Receptor Tyrosine Kinase DDR1
    Rahim Abdulhussein, Diana H.H. Koo, Wolfgang F. Vogel · 2007 · Journal of Biological Chemistry
  78. Structure, domain organization, and different conformational states of stem cell factor-induced intact KIT dimers
    Yarden Opatowsky, Irit Lax, Francisco Tomé, Franziska Bleichert, Vinzenz M. Unger, Joseph Schlessinger · 2014 · Proceedings of the National Academy of Sciences
  79. Structural biology contributions to tyrosine kinase drug discovery
    Sandra W. Cowan‐Jacob, Henrik Möbitz, Doriano Fabbro · 2009 · Current Opinion in Cell Biology
  80. Combined Treatment with Silibinin and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Overcomes Drug Resistance Caused by T790M Mutation
    Jin Kyung Rho, Yun Jung Choi, Byung-Suk Jeon, Su Jin Choi, Gi Jeong Cheon, Sang‐Keun Woo, Hye-Ryoun Kim, Cheol Hyeon Kim, Chang‐Min Choi, Jae Cheol Lee · 2010 · Molecular Cancer Therapeutics
  81. Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations
    Keita Masuzawa, Hiroyuki Yasuda, Junko Hamamoto, Shigenari Nukaga, Toshiyuki Hirano, Ichiro Kawada, Katsuhiko Naoki, Kenzo Soejima, Tomoko Betsuyaku · 2017 · Oncotarget
  82. Structural characterization of EGFR exon 19 deletion mutation using molecular dynamics simulation
    Mahlet Z. Tamirat, Marika K.A. Koivu, Klaus Elenius, Mark S. Johnson · 2019 · PLoS ONE
  83. Calmodulin‐mediated regulation of the epidermal growth factor receptor
    Pablo Sánchez‐González, Karim Jellali, Antonio Villalobo · 2009 · FEBS Journal
  84. Tyrosine 370 phosphorylation of ATM positively regulates DNA damage response
    Hong-Jen Lee, Li Lan, Guang Peng, Wei‐Chao Chang, Ming‐Chuan Hsu, Ying‐Nai Wang, Chien Chia Cheng, Leizhen Wei, Satoshi Nakajima, Shih-Shin Chang et al. · 2015 · Cell Research
  85. Utilizing protein structure to identify non-random somatic mutations
    Gregory A Ryslik, Yuwei Cheng, Kei-Hoi Cheung, Yorgo Modis, Hongyu Zhao · 2013 · BMC Bioinformatics
  86. Detection EGFR exon 19 status of lung cancer patients by DNA electrochemical biosensor
    Xiongwei Xu, Xiuhua Weng, Changlian Wang, Wei-Wei Lin, Ai‐Lin Liu, Wei Chen, Xinhua Lin · 2016 · Biosensors and Bioelectronics
  87. New developments in the management of non-small-cell lung cancer, focus on rociletinib: what went wrong?
    Nele Van Der Steen, Chiara Caparello, Christian Diego Rolfo, Patrick Pauwels, Godefridus J. Peters, Elisa Giovannetti · 2016 · OncoTargets and Therapy
  88. Comparative surface geometry of the protein kinase family
    Elaine E. Thompson, Alexandr P. Kornev, Natarajan Kannan, Choel Kim, Lynn F. Ten Eyck, Susan Serota Taylor · 2009 · Protein Science
  89. Biochemical and structural basis for differential inhibitor sensitivity of EGFR with distinct exon 19 mutations
    Iris K. van Alderwerelt van Rosenburgh, David M. Lu, Michael J. Grant, Steven E. Stayrook, Manali A. Phadke, Zenta Walther, Sarah B. Goldberg, Katerina A. Politi, Mark A. Lemmon, Kumar Dilip Ashtekar et al. · 2022 · Nature Communications
  90. Receptor-Based Virtual Screening of EGFR Kinase Inhibitors from the NCI Diversity Database
    Kiattawee Choowongkomon, Orathai Sawatdichaikul, Napat Songtawee, Jumras P. Limtrakul · 2010 · Molecules
  91. Therapeutic control and resistance of the EGFR-driven signaling network in glioblastoma
    Francisco J Azuaje, Katja Tiemann, Simone P. Niclou · 2015 · Cell Communication and Signaling
  92. Structure of Full-Length Human PDGFRβ Bound to Its Activating Ligand PDGF-B as Determined by Negative-Stain Electron Microscopy
    Po‐Han Chen, Vinzenz M. Unger, Xiaolin L. He · 2015 · Journal of Molecular Biology
  93. EGFR Signaling: Friend or Foe for Cartilage?
    Ling Qin, Frank Beier · 2019 · JBMR Plus
  94. Renaissance of Allostery to Disrupt Protein Kinase Interactions
    Alejandro E. Leroux, Ricardo M. Biondi · 2019 · Trends in Biochemical Sciences
  95. Putting together structures of epidermal growth factor receptors
    Nicholas J. Bessman, Daniel M. Freed, Mark A. Lemmon · 2014 · Current Opinion in Structural Biology
  96. The structural basis for cancer treatment decisions
    Ruth Nussinov, Hyunbum Jang, Chung‐Jung Tsai · 2014 · Oncotarget
  97. Membrane Interaction of Bound Ligands Contributes to the Negative Binding Cooperativity of the EGF Receptor
    Anton S. Arkhipov, Yibing Shan, Eric T. Kim, David Elliot Shaw · 2014 · PLoS Computational Biology
  98. Chapter Six - The Ubiquitin Network in the Control of EGFR Endocytosis and Signaling
    Alexia Conte, Sara Sigismund · 2016 · Progress in molecular biology and translational science
  99. Efficacy of afatinib or osimertinib plus cetuximab combination therapy for non-small-cell lung cancer with EGFR exon 20 insertion mutations
    Hanako Hasegawa, Hiroyuki Yasuda, Junko Hamamoto, Keita Masuzawa, Tetsuo Tani, Shigenari Nukaga, Toshiyuki Hirano, Keigo Kobayashi, Tadashi Manabe, Hideki Terai et al. · 2018 · Lung Cancer
  100. Molecular dynamics simulation-guided drug sensitivity prediction for lung cancer with rare EGFR mutations
    Shinnosuke Ikemura, Hiroyuki Yasuda, Shingo Matsumoto, Mayumi Kamada, Junko Hamamoto, Keita Masuzawa, Keigo Kobayashi, Tadashi Manabe, Daisuke Arai, Ichiro Nakachi et al. · 2019 · Proceedings of the National Academy of Sciences